Targeted radiation therapy for treating acute myeloid leukemia
Official title: Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous Leukemia
Funded at Beckman Research Institute/city of Hope · NIH-11132214 · Data updated 2026-11-12
This study is testing new types of radiation treatments for people with relapsed or hard-to-treat acute myeloid leukemia (AML) to make them safer and more effective, especially for older patients or those with other health problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | March 7, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $738,698 |
| NIH project number | 1R01CA292596-01A1 |
| Project ID | NIH-11132214 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with relapsed or refractory acute myeloid leukemia, particularly older adults or those with comorbidities.
✕Less likely to help
Patients with early-stage acute myeloid leukemia or those who do not have relapsed or refractory disease may not benefit from this research.
What this research studies
This research focuses on developing innovative radiation therapies to treat patients with relapsed and refractory acute myeloid leukemia (AML). It aims to improve treatment outcomes by using targeted radioimmunotherapy and total marrow irradiation, which specifically targets cancerous cells while minimizing damage to healthy tissues. The approach is designed to be safer and more effective, particularly for older patients or those with other health issues who may not tolerate traditional treatments well. By enhancing the precision of radiation delivery, the study seeks to reduce relapse rates and improve overall survival.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients with acute myeloid leukemia, potentially leading to better survival rates.
How similar studies have gone: Previous studies have shown promising results with similar targeted radiation therapies, indicating potential for success in this novel approach.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Wong, Jeffrey Y — Beckman Research Institute/city of Hope
- Study coordinator: Wong, Jeffrey Y
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.